An article published this year in “JOURNAL OF HEMATOLOGY & ONCOLOGY”
using our PE-Cyanine7
anti-CD19, Cell
Cycle Analysis (PI / RNASE Solutiuon) and FITC
Annexin V Apoptosis Detection Kit with PI, by our customers from Cancer
Research Center-IBMCC (USAL-CSIC), Department of Hematology, University
Hospital of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL),
Salamanca, Spain, in the analysis of how DEPTOR maintains plasma cell
differentiation and favorably affects prognosis in multiple myeloma. Congrats
and Thanks.
Summary:
Background
The B cell maturation
process involves multiple steps, which are controlled by relevant pathways and
transcription factors. The understanding of the final stages of plasma cell
(PC) differentiation could provide new insights for therapeutic strategies in multiple
myeloma (MM). Here, we explore the role of DEPTOR, an mTOR inhibitor, in the
terminal differentiation of myeloma cells, and its potential impact on patient
survival.
Methods
The expression level of
DEPTOR in MM cell lines and B cell populations was measured by real-time
RT-PCR, and/or Western blot analysis. DEPTOR protein level in MM patients was
quantified by capillary electrophoresis immunoassay. RNA interference was used
to downregulate DEPTOR in MM cell lines.
Results
DEPTOR knockdown in H929 and
MM1S cell lines induced dedifferentiation of myeloma cells, as demonstrated by
the upregulation of PAX5 and BCL6, the downregulation of IRF4, and a clear
reduction in cell size and endoplasmic reticulum mass. This effect seemed to be
independent of mTOR signaling, since mTOR substrates were not affected by
DEPTOR knockdown. Additionally, the potential for DEPTOR to be deregulated in
MM by particular miRNAs was investigated. The ectopic expression of miR-135b
and miR-642a in myeloma cell lines substantially diminished DEPTOR protein
levels, and caused dedifferentiation of myeloma cells. Interestingly, the level
of expression of DEPTOR protein in myeloma patients was highly variable, the
highest levels being associated with longer progression-free survival.
Conclusions
Our results demonstrate
for the first time that DEPTOR expression is required to maintain myeloma cell
differentiation and that high level of its expression are associated with
better outcome.
Product link:
PE-Cyanine7 - anti Human CD19 - HIB19: http://www.immunostep.com/cd-antibodies/2765-cd19.html
Cell Cycle Analysis (PI / RNASE Solutiuon): http://www.immunostep.com/solutions-buffers-chemicals/1289-pi-rnase-solution.html
FITC Annexin V Apoptosis Detection
Kit with PI: http://www.immunostep.com/apoptosis-tools/3727-anxvkf-100t.html
No comments:
Post a Comment